InstalabLoading...
InstalabLoading...
When you want to know whether the symptoms you woke up with, or the exposure you had three days ago, are actually COVID-19, this is the test that gives you a direct answer. It looks for the virus itself, not your body's response to it, which means it can catch infection in the first hours and days, often before a rapid antigen test would turn positive.
A positive result tells you the virus is in your body right now and you can act, by isolating, starting antiviral treatment if eligible, or alerting close contacts. A negative result, especially when symptoms are present, can also be informative but should be interpreted in context, because timing and sample quality affect what the test can see.
The COVID-19 RNA test, often called RT-PCR (reverse transcription polymerase chain reaction), looks for fragments of viral genetic material from SARS-CoV-2 (the virus that causes COVID-19) in a respiratory sample, usually a nasal or throat swab. The lab amplifies any viral RNA present millions of times, which is why this method can detect even tiny amounts of virus.
Detecting RNA is not the same as detecting live, transmissible virus. Genomic RNA can persist in the airway for weeks after someone is no longer contagious. Studies show that growing live virus from samples becomes very unlikely once cycle threshold values exceed 24 or symptoms have lasted more than about 8 days, even when RNA is still detectable. So a positive RNA result confirms exposure to the virus and active or recent infection, but it does not always mean you are still infectious.
Higher viral RNA levels are not just a curiosity. Across multiple studies, the amount of virus detectable in the body tracks with how sick people get.
In a cohort of 250 hospitalized adults, viral RNA load in plasma was associated with critical illness and a dysregulated immune response. A separate analysis of 51 hospitalized patients found that virus circulating in the blood (called RNAemia) correlated strongly with disease severity, worse outcomes, and inflammatory markers. A study of 191 patients reported that detectable virus in serum predicted clinical deterioration, oxygen needs, and complications outside the lungs.
A meta-analysis pooling multiple studies concluded that RNAemia is associated with disease severity, ICU admission, and death. The largest analysis to date, covering 259,511 people, found that high viral load at first sampling predicted severe infection or death across all age groups, even in vaccinated individuals.
In a study of 29 people with persistent symptoms after acute illness, 45% had detectable viral RNA in plasma, suggesting the virus may continue to linger in some bodies long after the initial infection appears resolved. RNA was also found in stool and urine in this group. The clinical meaning of this is still being worked out, but it raises the possibility that some long COVID symptoms reflect ongoing viral activity rather than purely post-infectious damage.
Not all viral RNA is the same. Genomic RNA is the full viral genetic blueprint and can stick around for weeks. Subgenomic RNA is produced only when the virus is actively replicating inside your cells, and its presence lines up much better with whether the virus can still be grown in the lab. In a healthcare worker study, subgenomic RNA was mostly positive only in the first 7 days of illness and only above certain viral load thresholds, matching how long people are likely to be contagious.
Most clinical labs report only standard RNA (genomic) detection, but subgenomic RNA testing is becoming more available and offers a sharper read on whether you still pose a transmission risk.
Where the swab is taken from changes how often the test catches infection. Across studies of test sensitivity, the differences are large:
| Sample Site | Sensitivity |
|---|---|
| Bronchoalveolar lavage (deep lung wash) | About 93 out of 100 cases caught |
| Sputum (coughed-up mucus) | About 72 out of 100 |
| Nasal swab | About 63 out of 100 |
| Throat swab | About 32 out of 100 |
Source: Watson et al., BMJ 2020; Yang et al., Innovation 2020. What this means for you: a single negative throat swab is not strong evidence that you do not have COVID-19. Nasal swabs are the standard for at-home and most clinic testing, and they perform reasonably well, but if symptoms are clear and the test is negative, retesting in 24 to 48 hours or using a different sample type is reasonable.
This is a qualitative test for most clinical labs. Your result will come back as one of three categories: detected (positive), not detected (negative), or inconclusive. Some labs also report a cycle threshold (Ct) value, which is a rough proxy for how much virus was present. Lower Ct numbers mean more virus.
Cycle threshold values are not standardized across labs and assay platforms, so comparing a Ct from one lab to another is not meaningful. As a rough orientation drawn from research:
| Result | What It Suggests |
|---|---|
| Not detected | No active infection captured by this sample, though early infection or sample timing can produce false negatives |
| Detected, low Ct (under about 24) | Higher viral load, more likely to be in an actively infectious phase |
| Detected, high Ct (above about 30 to 35) | Low viral load, possibly late in infection or residual RNA without live virus |
These thresholds come from research studies and vary by assay. Compare results within the same lab using the same assay over time for the most meaningful trend. A single Ct value should never be used in isolation to decide whether you are still contagious.
Several factors can produce a result that does not match your true infection status:
Most people do not need serial RNA testing. The exception is when you want to confirm clearance for return-to-work, time-sensitive surgery, or to evaluate persistent symptoms. If you test positive and want to retest, doing so within the first 5 days has limited utility because most people remain RNA positive. Repeat testing after day 7 to 10, ideally combined with subgenomic RNA testing if available, gives a more useful read on whether the virus is still active.
For monitoring long COVID, plasma, stool, or urine RNA testing is exploratory but may help confirm whether ongoing symptoms align with detectable viral persistence. This is not yet standard practice and results should be interpreted with a clinician familiar with post-acute COVID-19.
A positive RNA test, especially within 5 days of symptom onset, opens a treatment window. If you are at higher risk of severe disease (older age, immunocompromised, multiple chronic conditions), this is when antiviral therapy is most effective. Contact a clinician quickly to discuss options like nirmatrelvir/ritonavir or remdesivir, which work best when started early.
For most healthy adults, a positive result means isolation, symptom monitoring, and rest. Seek urgent care if you develop chest pain, severe shortness of breath, confusion, or oxygen saturation below 94% on a pulse oximeter. A negative result during symptomatic illness, especially with a known exposure, should prompt either a repeat RNA test in 24 to 48 hours or a different sample type, because one negative is not enough to rule out COVID-19 when suspicion is high.
Beyond the immediate infection, alongside an RNA test it can be useful to check inflammatory markers like CRP (C-reactive protein), D-dimer, and a complete blood count if you become moderately or severely ill, because elevated levels of these markers track with worse outcomes and can guide whether closer monitoring or hospitalization is needed.
Evidence-backed interventions that affect your COVID-19 RNA level
COVID-19 RNA is best interpreted alongside these tests.